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Abstract
BHK-21 cells persistently infected with foot-and-mouth disease virus (FMDV) can be cured of virus by treatment with the antiviral
nucleoside analogue ribavirin. To study whether the process involved an increase in the number of mutations in the mutant spectrum of the
viral population, viral genomes were cloned from persistently infected cells treated or untreated with ribavirin. An increase of up to 10-fold
in mutation frequencies associated with ribavirin treatment was observed in the viral genomes from the treated cultures as compared with
parallel, untreated cultures. To address the possible mechanisms of enhanced mutagenesis, we investigated the mutagenic effects of ribavirin
together with guanosine, and mycophenolic acid in the presence or absence of guanosine. Changes in the intracellular nucleotide
concentrations were determined for all treatments. The results suggest that the increased mutation frequencies were not dependent on
nucleotide pool imbalances or due to selection of preexisting genomes but they were produced by a mutagenic action of ribavirin.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Picornaviruses are the causative agents of many impor-
tant human and animal diseases, associated with either acute
or persistent infections (Racaniello, 2001; Semler and Wim-
mer, 2002). Foot-and-mouth disease virus (FMDV) is a
picornavirus of the genus Aphthovirus that causes the eco-
nomically most important disease of farm animals world-
wide (Sobrino et al., 2001). FMDV usually causes an acute
infection in animals, but it may also establish long-term
persistent infections in ruminants (van Bekkum et al., 1959;
Salt, 1993) and in cell culture (De la Torre et al., 1985).
During persistent infections of cattle established with bio-
logical clones of FMDV, continuous genetic and antigenic
evolution of the virus, with rates of fixation of mutations of
up to 7  102 substitutions per nucleotide and year, was
recorded (Gebauer et al., 1988). A system of BHK-21 cells
persistently infected with FMDV clone C-S8c1 was estab-
lished (De la Torre et al., 1985). The characterization of this
system suggested a steady-state persistent infection, with
the majority of cells displaying viral antigens, and the virus
and cells undergoing a coevolutionary process in which the
cells became gradually resistant to FMDV and the virus
gradually more virulent for the parental BHK-21 cells (De
la Torre et al., 1988, 1989; Dı´ez et al., 1990; Martin-
Hernandez et al., 1994). The nucleoside analogue ribavi-
rin (1--D-ribofuranosyl-1,2,3-triazole-3-carboxamide; Rib)
was effective in eliminating FMDV from persistently in-
fected cells (De la Torre et al., 1987) without significant
decrease of cell viability, but the mechanism of its anti-
FMDV activity is not known. Rib has shown antiviral ac-
tivity against a number of RNA and DNA viruses (Sidwell
et al., 1972; reviewed in Snell, 2001). Rib is phosphorylated
by cellular enzymes into ribavirin mono-, di-, and triphos-
phate (RMP, RDP and RTP, respectively) (Streeter et al.,
1973; Zimmerman and Deeprose, 1978) and exerts its an-
tiviral effect through various mechanisms: competitive in-
hibition of inosine monophosphate dehydrogenase (IM-
PDH; EC 1.1.1.205), which reduces the intracellular
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concentrations of guanine nucleotides (Franklin and Cook,
1969; Streeter et al., 1973), inhibition of some viral RNA-
dependent RNA polymerases (Eriksson et al., 1977; Wray et
al., 1985a,b; Toltzis et al., 1988; Fernandez-Larsson et al.,
1989), inhibition of mRNA cap formation (Goswami et al.,
1979; Scheidel and Stollar, 1991), and enhancement of Th1
antiviral immune responses (Hultgren et al., 1998; Ning et
al., 1998). Recently, it has been shown that Rib exerts an
antiviral action against poliovirus and hepatitis C virus
(HCV) associated with enhanced mutagenesis, as a result of
incorporation of RMP by poliovirus and HCV polymerases
(Crotty et al., 2000, 2001; Maag et al., 2001). The muta-
genic activity resulted from equal pairing of Rib with cyti-
dine and uridine during viral RNA synthesis.
The present study was undertaken to investigate whether
Rib-mediated curing of virus from cells persistently infected
with FMDV involved enhanced mutagenesis of the virus.
Since the effects of IMPDH inhibition can be reversed by
addition of 100 M guanosine, compensating for the re-
duced de novo synthesis of guanine nucleotides (Zimmer-
man and Deeprose, 1978; Kerr, 1987; Landford et al.,
2001), we analyzed the effects of (1) Rib alone, (2) Rib
together with guanosine, to measure the effects under con-
ditions in which cellular GTP concentrations were not de-
pleted, (3) mycophenolic acid (MPA), a noncompetitive
inhibitor of IMPDH with apparently no other mechanisms
of action, to measure the effects of IMPDH inhibition
(Lowe et al., 1977; Lee et al., 1985; Sintchak et al., 1996),
and (4) MPA together with guanosine to study whether
MPA had effects other than IMPDH inhibition. Nucleotide
sequences of the regions coding for VP1 (capsid protein)
and 3D (polymerase) of viral molecular clones were deter-
mined, and changes in intracellular nucleotide pools were
analyzed. The results support a mutagenic action of Rib
associated with curing of FMDV from persistently infected
cells.
Results
Effects of antiviral treatments on viral production of
persistent FMDV
Rib and MPA are inhibitors of the cellular enzyme
IMPDH, and the effects of this inhibition can be reversed by
addition of guanosine (Zimmerman and Deeprose, 1978;
Kerr, 1987; Lanford et al., 2001). In order to compare the
antiviral efficiencies of these two IMPDH inhibitors, per-
sistently infected cells of passage 40 were treated for 3 days
with 100 or 500 M Rib, 15 M MPA, or standard culture
medium, each of these in the presence or absence of up to
100 M guanosine (Fig. 1). None of the treatments had a
clear antiviral effect during the first 24 h. High concentra-
tions of guanosine in combination with 100 M Rib or 15
M MPA resulted in an increase of virus production during
the first 24 h. After 2 days, the antiviral effect was evident
in all treatments containing Rib or MPA. This antiviral
effect was significantly suppressed by guanosine in a dose-
dependent manner (Fig. 1). After 3 days, viral titers became
barely detectable in treatments involving 100 or 500 M
Rib together with 0 to 20 M guanosine, while 100 M
guanosine was able to suppress the antiviral effect consid-
erably. Treatments with MPA in combination with
guanosine had similar results, but viral titers were somewhat
higher in all cases. Hence, the antiviral effect of Rib was
stronger than that of MPA against FMDV in persistently
infected cells.
Effects of antiviral treatments on intracellular nucleotide
pools
The drug concentrations used were adjusted in prelimi-
nary measurements so that the effects of the treatments with
Fig. 1. FMDV production by persistently infected cells subjected to various
treatments. Samples were taken from the media at 1, 2, and 3 days after
adding the drugs to the media on confluent cell monolayers. Culture
medium was changed daily after samples were taken. A parallel control
experiment without drugs cannot be described here, since in the absence of
drugs, the high virus production in a confluent cell monolayer produced a
cytopathic effect (de la Torre et al., 1985). Results are the average of two
experiments, and differences between corresponding samples did not ex-
ceed 1 logarithm. Procedures for cell culture and titration of FMDV are
described under Materials and methods.
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Rib and MPA in intracellular nucleotide pools should be
similar. In order to verify this, samples were taken at vari-
ous time points during each treatment, and nucleoside
triphosphates were separated and quantitated by high-per-
formance liquid chromatography (HPLC; typical chromato-
grams are shown in Figs. 2A and B). The basal levels of
intracellular ribonucleoside triphosphates in persistently in-
fected BHK-21 cells were approximately half of those in
uninfected BHK cells (Fig. 2C). Treatment of persistently
infected cells with either Rib (100 or 500 M) or MPA (15
M) produced similar changes in the intracellular ribonu-
cleoside triphosphate levels. As expected from the inhibi-
tory effect of MPA and Rib on IMPDH (Fig. 3A), GTP
concentration was reduced 3- to 4-fold of its initial level
during the first 4 to 8 h of treatment, and remained at similar
levels after 3 days of culture. Addition of 100 M
guanosine together with 500 M Rib produced a 5-fold
increase in the GTP concentration (Fig. 3B); this guanosine
concentration was used since 20 M guanosine was not
sufficient to maintain GTP concentrations above the initial
level for 24 h, and the higher concentration resulted in
substantially elevated viral production in the presence of the
drugs (Fig. 1). CTP and UTP levels were increased in 8 h up
to 1.4- to 1.7-fold of their initial values, respectively, and
then began declining toward the normal concentrations
(data not shown). ATP levels were not affected by treat-
ments with MPA or 100 M Rib, but exposure to 500 M
Rib reduced ATP concentrations by 20 to 40%, possibly due
to the use of ATP in the phosphorylation of Rib to RMP by
adenosine kinase (Fig. 3A). Since both Rib and MPA are
inhibitors of IMPDH, treatments with these drugs should
lead to accumulation of IMP. As expected, the IMP con-
centration rose more than 10-fold and about 30-fold from
the initial level of approximately 0.001 fmol per cell due to
treatments with 500 M Rib and 15 M MPA, respectively
(data not shown).
Intracellular concentration of ribavirin triphosphate in
cells persistently infected with FMDV
To determine the kinetics of intracellular accumulation
of ribavirin triphosphate, persistently infected cells were
extracted at different times after addition of Rib and the
nucleotide concentrations were examined by HPLC. RTP
was identified in the nucleotide pattern (Fig. 2B) by com-
parison with commercial RTP (Jena Bioscience). The intra-
cellular RTP concentration reached a maximum of approx-
imately 5 fmol/cell at 8 h after exposure and then decreased
slightly during the next 16 h (Figs. 3C and D). We conclude
that Rib penetrates into BHK-21 cells persistently infected
with FMDV, where it is converted into RTP that accumu-
lates in the cells, and addition of Rib in culture media
induces alterations of intracellular nucleotide pools ex-
pected from the inhibition of IMPDH.
Mutant spectrum complexity of persistent FMDV
subjected to antiviral treatments with and without
guanosine
To evaluate whether Rib might act as a mutagen of
FMDV, and to study whether the possible mutagenic effects
could be due to IMPDH inhibition and the resulting pertur-
bations in the intracellular nucleotide concentrations, we
determined the nucleotide sequences around the VP1-cod-
ing region and of the 3D-coding region of individual FMDV
cDNA clones derived from persistent viral populations
treated with 100 or 500 M Rib, or 15 M MPA, in the
presence and absence of 100 M guanosine (Table 1). The
Fig. 2. Determination of ribonucleoside triphosphate concentrations in
persistently infected and uninfected BHK-21 cells. Confluent cell mono-
layers were extracted as described under Materials and methods, and the
nucleoside triphosphates were separated and quantitated by HPLC. (A)
HPLC chromatogram showing the elution profile from untreated cells
persistently infected with FMDV. The absorbance at 254 nm is expressed
in milliabsorbance units (mAU). (B) HPLC chromatogram showing the
elution profile from cells persistently infected with FMDV, treated for 4 h
with Rib. Note the absence of the RTP peak in the control treatment, and
the large increase in the amount of IMP, compared with the profile shown
in panel A. (C) Ribonucleoside triphosphate concentrations in uninfected
BHK-21 cells and BHK-21 cells persistently infected with FMDV. The
results are averages of 5 independent determinations, and the standard
deviations are shown.
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FMDV genomic regions around the VP1-coding region (nu-
cleotides 3193–3869) and the RNA-dependent RNA poly-
merase 3D (nucleotides 6610–8019) were amplified and
cloned under conditions designed to ensure that cDNA
clones reflected the complexity of the RNA population
(described under Materials and methods).
Mutation frequencies of FMDV produced by cells
treated with Rib were 4 to 10 times higher than those found
in virus from untreated cells, while Shannon entropies (a
measurement of the number of different sequences in the
mutant spectrum) increased 2- to 7-fold (Table 1). The
addition of guanosine during Rib treatment did not affect
significantly the complexity of the mutant spectrum of the
3D-coding region, and reduced less than 2-fold the com-
Fig. 3. Effects of Rib and MPA on intracellular nucleotide concentrations. (A) Metabolic pathways relevant to the present study. In de novo synthesis of purine
nucleotides, guanine derivatives are synthesized from IMP via xanthosine monophosphate (XMP), while adenine nucleotides are synthesized from IMP via
adenylosuccinate. GTP is a phosphate donor for adenylosuccinate synthetase, and ATP is a phosphate donor for adenosine kinase. The presence of MPA or
RMP results in GTP depletion through inhibition of IMPDH, and this effect can be compensated by addition of exogenous guanosine. Symbols: solid lines,
metabolic reactions; double lines, inhibition; punctuated lines, donor molecules. The figure is based on previously published data (Franklin and Cook, 1969;
Streeter et al., 1973; Lowe et al., 1977; Lee et al., 1985; Balzarini et al., 1991). (B) Changes in GTP concentrations associated with antiviral treatments of
cells persistently infected with FMDV. Concentrations are shown as a function of time after initiation of the treatments for persistently infected cells treated
with 500 M Rib (●), 15 M MPA (), 500 M Rib with 100 M guanosine (), and normal medium (Œ). (C) The peak corresponding to RTP in the HPLC
elution profiles after treatments of 2, 4, 8, and 16 h with 500 M Rib, and 8 h of treatment with normal medium. (D) RTP accumulation in persistently infected
cells. Intracellular RTP concentrations were determined from cell cultures at the indicated times after addition of 500 M Rib. The intracellular RTP
concentrations were roughly proportional to the Rib concentrations in the media, with 500 M Rib yielding apparently at least 5 times more RTP in the cells
than 100 M Rib. However, RTP absorbed poorly at the 254 nm wavelength used, and therefore the concentrations achieved in the presence of 100 M Rib
were close to the detection limit and could not be reliably quantitated. Assuming a cell volume of 3.6 ml/109 cells (Traut, 1994), the maximal intracellular
RTP concentration obtained was approximately 1.5 to 2 mM. The RTP peaks in the chromatograms were quantitated as described under Materials and
methods.
342 A. Airaksinen et al. / Virology 311 (2003) 339–349
plexity of the VP1-coding region. Therefore, Rib was found
to be mutagenic to FMDV, and this effect was largely
independent of the depletion of intracellular GTP concen-
tration.
The MPA-induced mutation frequencies were 2.5- to
6-fold higher than in the untreated viral population, remain-
ing clearly below the ones observed with Rib treatments
(Table 1). Shannon entropies increased 3- to 4-fold. Addi-
tion of guanosine in the MPA treatment abolished the mu-
tagenic effect, suggesting that the mutations were due to
IMPDH inhibition (Table 1).
Types of mutations found
In treatments with 100 or 500 M Rib, with or without
guanosine, a total of 57 mutations were found of the types
C3U and G3A, and 11 mutations of the types U3C and
A3G (Table 2). Mutations C3U and G3A should be
expected if mutations resulted from Rib incorporation op-
posite to C, while mutations U3C and A3G should be
expected if mutations resulted from Rib incorporation op-
posite to U. In contrast to the results with Rib-treated pop-
ulations, treatment with MPA did not show the same mu-
tational bias: there were 10 mutations of the types C3U
and G3A, and 9 mutations of the types U3C and A3G.
Synonymous and nonsynonymous mutations were relatively
uniformly distributed along the genomic regions analyzed
(Fig. 4). A total of 97 mutations were found in this study, 46
in the 3D-coding region (22 of which led to amino acid
substitutions) and 51 in the VP1 region (25 amino acid
substitutions). Since 3D consists of 470 amino acids and
VP1 of 209 amino acids, the results show a lower accept-
ability of mutations in the polymerase-coding region. The
results support a significant mutagenic effect of Rib asso-
ciated with curing of FMDV from persistently infected
cells.
Discussion
Persistently infected cells can be cured of FMDV by the
nucleoside analogue Rib. Previous studies from several lab-
oratories have indicated that Rib exerts its antiviral effects
through different biochemical mechanisms, depending on
the virus and the host cell (Malinoski and Stollar, 1981;
Jordan et al., 1999), and in many cases the antiviral effect
cannot be ascribed to a single mechanism. Rib and MPA are
both inhibitors of the cellular enzyme IMPDH, producing a
significant reduction in the intracellular GTP concentration
(Franklin and Cook, 1969; Streeter et al., 1973). Contrary to
Rib, there are no other known targets for MPA apart from
IMPDH (Franklin and Cook, 1969; Lowe et al., 1977; Lee
et al., 1985). Treatment with MPA had a clear antiviral
effect that was suppressed when GTP pools were restored
by adding guanosine exogenously. Thus, MPA was able to
reduce viral replication efficiency by altering the host cell
ribonucleotide pools, as a result of IMPDH inhibition.
Treatment of cells with Rib reduced the intracellular
GTP concentration 3- to 4-fold, in agreement with previous
reports (Lowe et al., 1977; Wray et al., 1985b; Balzarini et
Table 1
Genetic heterogeneity in the mutant spectrum of persistent FMDV populations after treatments with Rib or MPA












VPI 100 M Rib 6770 8 3 12 0.65
100 M Rib  100 M gua 6770 5 5 7.4 0.53
500 M Rib 6770 14 9 21 0.86
500 M Rib  100 M gua 6770 9 4 13 0.65
15 M MPA 13540 11e 6e 8.1 0.41
15 M MPA  100 M gua 6770 2 1 3.0 0.14
Normal medium 6770 2 1 3.0 0.28
3D 100 M Rib 14100 10 6 7.1 0.65
100 M Rib  100 M gua 14100 8 3 5.7 0.65
500 M Rib 14100 8 5 5.7 0.76
500 M Rib  100 M gua 14100 11 7 7.8 0.94
15 M MPA 14100 6 3 4.3 0.53
15 M MPA  100 M gua 14100 2 — 1.4 0.28
Normal medium 14100 1 — 0.7 0.14
a Concentrations of Rib, MPA, and guanosine (gua) added to the culture media are indicated.
b The number of cDNA clones that were sequenced was 10 for each treatment for both VP1 and 3D, except for the VP1 region of clones obtained from
the treatment with 15 M MPA, for which 20 clones were sequenced. This gives the total number of nucleotides sequenced, which is indicated in this column.
c Mutation frequency is calculated dividing the number of different mutations found in the aligned sequences by the total number of nucleotides sequenced.
d The normalized Shannon entropy is calculated as [¥i(pi  ln pi)]/ln N, in which pi is the proportion of each sequence of the mutant spectrum and N
is the total number of sequences compared (Volkenstein, 1994).
e Note that a larger number of VP1 clones was sequenced here.
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al., 1991). Changes in ribonucleotide levels were similar to
those observed with MPA, and therefore, the antiviral ef-
fects of these two compounds resulting from IMPDH inhi-
bition should be similar. However, the antiviral effect of Rib
was stronger, and while the effects of 15 M MPA and 100
M Rib were largely reversed by 100 M guanosine, treat-
ment with 500 M Rib had a strong antiviral effect even in
the presence of 100 M guanosine (Fig. 1). In agreement
with these observations, it has been previously shown that
depending on the system, the antiviral effects of Rib may be
Table 2
Types of mutations in the mutant spectrum of the persistent FMDV found after various antiviral treatments
Mutation types Number of mutants of each type after the indicated treatmentsa
R500 R500 R100 R100 MPAb MPA Control
G100 G100 G100
Transitions A3G — — 2 2 5 1 —
U3C 3 3 1 — 2 1 —
G3A 5 8 6 3 3 1 —
C3U 13 7 8 7 5 1 3
Transversions A3C 1 — — — — — —
A3U — 1 — 1 — — —
C3A — — — — 1 — —
C3G — — — — — — —
G3C — — — — — — —
G3U — — 1 — — — —
U3A — 1 — — 1 — —
U3G — — — — — — —
a The treatments were as follows: R500, 500 M Rib; R100, 100 M Rib; MPA, 15 M mycophenolic acid; G100, 100 M guanosine; control, normal
growth medium. The number of cDNA clones sequenced, the total number of mutations, and their consequences for mutant spectrum complexity associated
with each treatment are summarized in Table 1. Procedures for nucleotide sequence determination are described under Materials and methods.
b Note that in this experiment, 20 clones of VP1 were sequenced instead of 10.
Fig. 4. Location of the mutations found in the VP1- and 3D-coding regions of FMDV after subjecting the persistently infected cells to various antiviral
treatments. Each line represents the 10 clones sequenced from each population (20 clones from the VP1 region of the MPA-treated population). R500, 500
M Rib: R100, 100 M Rib; G0, no guanosine; G100, 100 M guanosine; MPA, 15 M MPA; Control, normal media without drugs. Symbols: amino acid
substitutions (}); silent mutations (). Sequence numbering is according to (Escarmı´s et al., 1999). Procedures for nucleotide sequence determination are
described under Materials and methods.
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either partially or mostly reversed by guanosine (Streeter et
al., 1973; Wray et al., 1985b; Scheidel and Strollar, 1991;
Jordan et al., 1999), and that the dose-dependent antiviral
activity can increase even when the additional drug has no
further effect on GTP pools (Wray et al., 1985b). In some
systems the antiviral activity of Rib seems to be either
independent of the IMPDH inhibition (Smee and Matthews,
1986) or limited to the same level as with other IMPDH
inhibitors (Wray et al., 1986; Lanford et al., 2001). There-
fore, in some viral systems but not others, Rib possesses an
antiviral activity that is independent of the effects on nu-
cleotide pools.
Recent studies have raised the possibility that Rib could
exert its action through increased mutagenesis (Crotty et al.,
2000, 2001; Maag et al., 2001; Contreras et al., 2002). We
found an increase in mutation frequencies due to treatments
with either Rib or MPA, although the latter treatment re-
sulted in a less pronounced increase in mutant spectrum
complexity (Table 1). The mutagenic effect of MPA was
abolished by addition of guanosine, while that of Rib was
only slightly reduced. The mutations found in MPA-treated
populations were presumably due to an increased number of
transition mutations that were favored by changes in the
relative intracellular ribonucleotide concentrations, al-
though there was no preference for C3U and G3A mu-
tations that might be expected due to GTP depletion (Table
2). Thus, Rib had an additional source of antiviral activity
not ascribable to IMPDH inhibition that was consistent with
mutagenesis through incorporation of Rib into the FMDV
genomic RNA. As for other RNA viruses, FMDV replica-
tion is error prone and the mutation rates are close to an
error threshold that sets a limit for maintenance of genetic
information (Swetina and Schuster, 1982; Eigen and
Biebricher, 1988; Holland et al., 1990; Drake and Holland,
1999; Eigen, 2000; Sierra et al., 2000; Pariente et al., 2001).
Curing of persistently infected cells from FMDV by Rib
thus appears to provide yet another example of virus ex-
tinction through lethal mutagenesis (Eigen, 2002).
Nucleotide sequencing of the VP1 and 3D genes of viral
cDNA clones obtained from the mutant spectrum of persis-
tent FMDV after various drug treatments indicates a muta-
genic action of Rib. The observed Rib-induced mutation
frequencies are close to those reported for poliovirus and
HCV (Crotty et al., 2001; Contreras et al., 2002). Mutation
frequencies in untreated viral populations were similar to
those found earlier in FMDV from persistent or cytolytic
infections (De la Torre et al., 1988; Sierra et al., 2000; Arias
et al., 2001; Pariente et al., 2001), while they were 2- to
10-fold higher in populations treated with Rib or MPA. The
mutagenic effect of Rib was only mildly suppressed by
guanosine addition, indicating that the mutations were not
due to ribonucleotide pool imbalances resulting from
IMPDH inhibition. The reduced amount of GTP might,
however, favor incorporation of Rib into the viral RNA
(RTP:GTP ratios were up to 10; compare Figs. 3B and D),
or increase the number of transition mutations through in-
corporation of adenosine instead of guanosine. The latter
possibility is less likely, since Rib decreased the ATP pools
more than MPA, and therefore the GTP:ATP ratios were
less affected by Rib treatment. It could be argued that Rib
cured FMDV by some other mechanism and that the in-
crease in mutant spectrum complexity was the result of
dominance of minority components of the mutant spectrum.
This is highly unlikely because minority genomes analyzed
from FMDV mutant spectra rarely show a mutational bias
of the type seen in the Rib-treated FMDV. Furthermore, in
no previous case a mutant spectrum of FMDV showed an
increase in complexity unless the population had been sub-
jected to mutagenic treatments (Sierra et al., 2000; Pariente
et al., 2001). The amino acid substitutions were also rather
uniformly distributed within both VP1 and 3D (Fig. 4). In
VP1, 43% of the mutations occurred at residues that were
not accessible to the solvent (Lea et al., 1994; Mateu et al.,
1994), implying a mutagenic action since during FMDV
evolution, mutations mostly occur in the exposed residues
of the capsid (Semler and Wimmer, 2002, and chapters
therein).
Rib treatment resulted in an increase in C3U and G3A
mutations (Table 2), as reported earlier for poliovirus
(Crotty et al., 2000, 2001). The frequencies of the other two
types of transition mutations (U3C and A3G) were much
lower, and similar in all treatments. This is in contrast to
what would be expected if Rib paired equally well with
cytidine and uridine, as has been demonstrated for the po-
liovirus and HCV polymerases in vitro (Crotty et al., 2000,
2001; Maag et al., 2001). Mutations C3U and G3A
should both occur if Rib is incorporated opposite to cyti-
dine, either during negative strand synthesis (C3U) or
during positive strand synthesis (G3A). It would be pos-
sible to explain the preference for these two mutations by
favored Rib incorporation when the competing GTP is lim-
ited, or as a result of spontaneous transitions due to low
GTP concentration. However, these explanations are not
consistent with the data obtained with treatments involving
Rib together with guanosine, since C3U and G3A mu-
tations were more abundant in these viral populations as
well. It seems that during FMDV replication Rib does have
a preference to be incorporated opposite to cytidine instead
of uridine, or that uridine is incorporated more frequently
than cytidine when Rib is present in the template.
The mutation frequencies found in all Rib treatments,
with or without guanosine, imply an average of 7 mutations
per genome. Due to negative selection of at least the poly-
merase-coding region, it is possible that the actual muta-
genic effect was stronger than that reflected by the clones
sequenced, since the small difference in mutation frequen-
cies obtained in treatments with 500 or 100 M Rib with
100 M guanosine (Table 1) is probably not sufficient to
explain the large difference in the antiviral effects of these
two treatments (Fig. 1). Alternatively, other effects of Rib
such as inhibition of viral RNA synthesis could participate
in curing of FMDV (Snell, 2001). Inhibition of cap forma-
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tion should not have an antiviral effect on FMDV, since
picornaviruses use a cap-independent initiation of transla-
tion (Jang et al., 1988; Pelletier and Sonenberg, 1988), and
they do not depend on capped cellular mRNA molecules for
replication (reviews in Semler and Wimmer, 2002).
Rib-mediated mutagenesis has been reported for polio-
virus, hepatitis C virus, Hantaan virus and possibly GB virus B
(Crotty et al., 2000; Lanford et al., 2001; Maag et al., 2001;
Contreras et al., 2002; Severson et al., 2003), while no mu-
tagenesis was found for lymphocytic choriomeningitis virus
(LCMV) despite a potent antiviral effect of Rib (Ruı´z-Jarabo et
al., 2003). The HCV RNA polymerase was found to incorpo-
rate Rib and to induce mutagenic base pairing, albeit less
efficiently than the poliovirus RNA polymerase (Maag et al.,
2001), and Rib was mutagenic for HCV in a plasmid-based
replication system (Contreras et al., 2002). In HCV patients,
however, no evidence of mutagenesis has been seen (Gerotto et
al., 1999; Querenghi et al., 2001; Sookoian et al., 2001), pos-
sibly due to the low Rib concentrations reached at the sites of
viral replication. Consistent with earlier findings (Rankin et
al., 1989), we found Rib to accumulate inside the cells,
yielding maximal concentrations of approximately 1.5 to 2
mM RTP in the presence of 500 M Rib in the medium
(legend to Fig. 3D). The maximal in vivo Rib concentration
at the site of infection has been reported to be 600 to 800
M in respiratory fluids after small-particle aerosol admin-
istration (Gilbert and Knight, 1986), while intravenous ad-
ministration was estimated to result in peak concentrations
of approximately 20–150 M in serum, which rapidly de-
clined to levels as low as 1 M (Connor et al., 1993; Jordan
et al., 2000). Oral administration resulted in concentrations
below 20 M in serum and 10 M in cerebrospinal fluid
(Crumpacker et al., 1986; Ogle et al., 1989; Connor et al.,
1993; Anderson and Rahal, 2002). All these values in vivo
are clearly lower than the concentrations that have been
found to be mutagenic in cell culture, and they may not be
sufficient for a significant mutagenic activity of RTP.
In summary, we have shown that the antiviral effect of
Rib on FMDV in persistent infection is caused by at least
two mechanisms: (1) direct mutagenesis and (2) imbalances
in ribonucleotide pools resulting from IMPDH inhibition.
Our results support Rib incorporation into viral RNA, but
suggest that Rib does not pair equally well with cytidine and
uridine. Further studies are needed to clarify the base pair-
ing and incorporation properties of RTP by viral poly-
merases in vitro and to investigate whether intracellular
concentrations of Rib could be high enough in vivo to allow
significant incorporation of the drug in the viral RNA.
Materials and methods
Cells, viruses, and treatments
The baby hamster kidney cell line (BHK-21), persis-
tently infected with FMDV C-S8c1, and procedures for its
maintenance have been characterized previously (De la
Torre et al., 1985, 1987, 1988, 1989). Persistently infected
cells at passage 40 were used. Cells were shedding virus to
the medium with maximal titers of about 105 PFU/ml (De la
Torre et al., 1988; Dı´ez et al., 1990). FMDV C-S8c1 is a
plaque-purified derivative of the natural isolate C1 Santa
Pau-Spain/70 (Sobrino et al., 1983). Drug treatments of
persistently infected cells were initiated as the cell mono-
layers reached confluence. The cells were washed with
normal medium [Dulbecco’s modified Eagle’s medium
(Gibco) supplemented with nonessential amino acids
(Gibco), 50 mg/ml gentamicin (Sigma), and 5% fetal calf
serum (Gibco)], and new media were added, containing Rib
(0, 100, or 500 M) or MPA (0 or 15 M; Sigma) in the
presence or absence of guanosine (0, 5, 20, or 100 M;
Sigma). The media were changed daily, and samples from
the media were taken immediately before each change. In
the experiments with Rib or MPA, the drugs did not cause
significant cytotoxicity, as initially confluent monolayers
remained confluent during the 3 days of treatment. After
24 h, the number of viable cells had increased by 40 % in
the untreated cultures, 15% in Rib-treated cultures, and 7%
in MPA-treated cultures.
Sample preparation for high-performance liquid
chromatography
To prepare samples from cell cultures for quantification
of ribonucleotide levels by HPLC, we used the system
described by Pogolotti and Santi (1982), with minor modi-
fications. Briefly, the cell monolayers ( 60 mm) were
washed with phosphate-buffered saline, treated with 300 l
of 0.6 M trichloroacetic acid, and incubated on ice for 10
min. The supernatants were collected and extracted with
1,1,2-trichlorotrifluoroethane (Sigma) containing 0.5 M tri-
n-octylamine (Sigma). The mixtures were vortexed for 10 s
and centrifuged 30 s at 12,000 g. The upper phase was
collected and immediately frozen at80°C, and upon thaw-
ing, the samples were analyzed immediately. The entire
treatment was performed at 0 to 4°C, using ice-cold solu-
tions. The ATP:ADP ratio was consistently above 20, indi-
cating minimal loss of the terminal phosphate during sample
preparation.
HPLC analysis of nucleotide pools
Nucleotides were separated using a 4.6  250-mm Par-
tisil 10 SAX column (Whatman) with a 4.6  30-mm
Partisil 10 SAX precolumn (Phenomenex). Around 25 pmol
of nucleotides in a total volume of 100 l were analyzed.
After washing the column with 18 ml of buffer A (7 mM
NH4H2PO4, pH 3.8), nucleotides were eluted with a linear
gradient prepared with 45 ml of buffer A and 45 ml of
buffer B (250 mM NH4H2PO4, 500 mM KCl, pH 4.5),
followed by a final wash with 30 ml of buffer B (Pogolotti
and Santi, 1982). The flow rate was 0.8 ml/min and the
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optical density of the eluant was continuously monitored at
254 nm. Nucleotide amounts were estimated from a stan-
dard curve obtained using samples containing known
amounts of each nucleotide eluted under the same condi-
tions. To correct for the fluctuations in the numbers of cells
analyzed, peak sizes were normalized against the well-
isolated and reproducible NAD peak of each sample, the
concentration of which was not affected by any of the
treatments. Chromatograms were analyzed using the Uni-
corn 3.00 software (Amersham Pharmacia Biotech). Nucle-
otide peaks were identified by comparison with the ob-
served retention times of commercial solutions of RTP
(Jena Bioscience), IMP, NAD (Sigma), ATP, ADP, CTP,
GTP, and UTP (Amersham Pharmacia Biotech). In addi-
tion, the identity of the NAD peak was confirmed by mass
spectroscopy as described below.
Mass spectrometry analysis
The identity of the presumed NAD peak was confirmed
by analyzing by matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry using an
externally calibrated Reflex III instrument (Brucker-Fran-
zen Analytic, Bremen, Germany) operating in the positive-
ion reflection mode. HPLC-collected fractions were lyoph-
ilized and resuspended in 50 l of distilled water. Part of
this sample (5 l) was then mixed with 10 l of a 10 mg/ml
solution of 2,4,6-trihydroxyacetophenone matrix in ethanol;
1 l of this mixture was dried down and subjected to
analysis.
PCR, molecular cloning, and sequencing
Viral RNA was purified from 300 l of persistently
infected cell culture supernatant using the RNeasy Mini Kit
(Qiagen). Reverse transcription and PCR were performed
with AMV reverse transcriptase (Promega) and high fidel-
ity Pwo DNA polymerase (Roche). Primers for PCR am-
plification of the 3D polymerase-coding region were
5-CAGAGCTCGACCCTGAACCGCA-3 (positions 6580–
6602 of the FMDV genome) and 5-GCCCCGAATTCAT-
TGTGC-3 (positions 8060–8043), designed to create tar-
get sites for restriction endonucleases SacI and EcoRI,
respectively. Primers for amplification of the VP1-coding
region were 5-CTTTGAGCTCCGGCTACCTGTG-3 (po-
sitions 3171–3192) and 5-GAGAAGAAGAAGGGC-
CCAGGGTTGGAC-3 (positions 3896–3870), with target
sites for restriction endonucleases SacI and BamHI, respec-
tively. Numbering of residues in the FMDV genome is
according to Escarmı´s et al. (1999). The PCR products were
digested using the indicated enzymes and ligated into the
polycloning site of plasmid pGEM-4Z (Amersham). Com-
petent Escherichia coli DH5 bacteria were transformed by
the plasmid and plated, and individual colonies were picked
for PCR amplification. PCR of the DNA from bacterial
colonies, together with negative controls, were performed
using AmpliTaq DNA polymerase (Perkin Elmer) and the
primers described above. The PCR products were se-
quenced entirely in both orientations with an ABI sequencer
using appropriately spaced primers, as previously described
(Sierra et al., 2000; Pariente et al., 2001).
Samples for the analysis of quasispecies complexity
Mutant spectrum heterogeneity was studied with viral
populations that had been treated with drugs for 48 h, and
some of these populations were approaching extinction at
the time of RNA extraction. It was therefore essential to
make sure that cloning and sequencing were performed
reliably from individual clones that reflected the authentic
RNA population rather than repeating the analysis with
PCR products amplified from the same original viral RNA
molecules. When analyzing n random amplification prod-
ucts from an RT-PCR performed with a sample containing
D RNA molecules (D can be regarded as the last dilution
found positive in PCR), the expected number of indepen-
dent clones (E) is given by E  D(1  ((D  1)/D)n [the
formula is modified from Airaksinen and Hovi, 1998]. In
the present work, 6 RT-PCR reactions were performed from
each RNA sample. In addition to 3 independent reactions
with undiluted RNA, reactions were also performed using
samples diluted 1:10, 1:20, and 1:40. In cases where the
1:40 dilution was positive in RT-PCR, one of the RT-PCR
obtained with undiluted RNA was used as the material for
cloning. Under these conditions, sequencing 10 clones
should give at least 8.9 independent sequences (D  40, n
 10, E 8.9). When the 1:40 dilution was not positive but
1:20 or 1:10 were, all 3 RT-PCR from undiluted RNA were
used in cloning, and the total of 10 sequences (4  3  3)
were derived from the 3 parallel cloning procedures (E 
9.4 or E  8.9 for dilutions 1:20 and 1:10, respectively).
The results demonstrate that these precautions were suffi-
cient, since only 3 different mutations, out of the 97 scored,
were found twice in a single population. For determination
of the mutation frequencies, generally 10 clones were se-
quenced of each of the seven persistent FMDV populations
subjected to various antiviral treatments. The exact numbers
of clones analyzed in each experiment are given under
Results and Table 1.
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